Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

CK Life Sciences Int'l. (Holdings)

DB:LSI
Snowflake Description

Fair value with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LSI
DB
HK$9B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research, development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
  • CK Life Sciences Int'l. (Holdings) has significant price volatility in the past 3 months.
LSI Share Price and Events
7 Day Returns
5.5%
DB:LSI
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
144.7%
DB:LSI
-13.2%
DE Biotechs
-20.9%
DE Market
LSI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CK Life Sciences Int'l. (Holdings) (LSI) 5.5% 6.5% 19.2% 144.7% 49.4% 16.2%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • LSI outperformed the Biotechs industry which returned -13.2% over the past year.
  • LSI outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
LSI
Industry
5yr Volatility vs Market

LSI Value

 Is CK Life Sciences Int'l. (Holdings) undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of CK Life Sciences Int'l. (Holdings) to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for CK Life Sciences Int'l. (Holdings).

DB:LSI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:LSI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 25%) (62.99%))
1.502
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.5
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.502 * 6.07%)
8.73%

Discounted Cash Flow Calculation for DB:LSI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for CK Life Sciences Int'l. (Holdings) is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:LSI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (HKD, Millions) Source Present Value
Discounted (@ 8.73%)
2020 360.52 Est @ 94.11% 331.58
2021 597.60 Est @ 65.76% 505.52
2022 871.98 Est @ 45.91% 678.42
2023 1,151.22 Est @ 32.02% 823.78
2024 1,407.93 Est @ 22.3% 926.62
2025 1,626.05 Est @ 15.49% 984.28
2026 1,800.49 Est @ 10.73% 1,002.39
2027 1,933.59 Est @ 7.39% 990.09
2028 2,031.38 Est @ 5.06% 956.68
2029 2,100.92 Est @ 3.42% 910.02
Present value of next 10 years cash flows HK$8,109.00
DB:LSI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= HK$2,100.92 × (1 + -0.39%) ÷ (8.73% – -0.39%)
HK$22,955.06
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= HK$22,955.06 ÷ (1 + 8.73%)10
HK$9,943.03
DB:LSI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= HK$8,109.00 + HK$9,943.03
HK$18,052.03
Equity Value per Share
(HKD)
= Total value / Shares Outstanding
= HK$18,052.03 / 9,611.07
HK$1.88
DB:LSI Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:LSI represents 0.12366x of SEHK:775
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.12366x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 1.88 x 0.12366
€0.23
Value per share (EUR) From above. €0.23
Current discount Discount to share price of €0.12
= -1 x (€0.12 - €0.23) / €0.23
50.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price CK Life Sciences Int'l. (Holdings) is available for.
Intrinsic value
>50%
Share price is €0.115 vs Future cash flow value of €0.23226
Current Discount Checks
For CK Life Sciences Int'l. (Holdings) to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • CK Life Sciences Int'l. (Holdings)'s share price is below the future cash flow value, and at a moderate discount (> 20%).
  • CK Life Sciences Int'l. (Holdings)'s share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CK Life Sciences Int'l. (Holdings)'s earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CK Life Sciences Int'l. (Holdings)'s earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LSI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in HKD HK$0.02
SEHK:775 Share Price ** SEHK (2020-04-03) in HKD HK$0.93
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CK Life Sciences Int'l. (Holdings).

DB:LSI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:775 Share Price ÷ EPS (both in HKD)

= 0.93 ÷ 0.02

49.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CK Life Sciences Int'l. (Holdings) is overvalued based on earnings compared to the Europe Biotechs industry average.
  • CK Life Sciences Int'l. (Holdings) is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does CK Life Sciences Int'l. (Holdings)'s expected growth come at a high price?
Raw Data
DB:LSI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 49.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CK Life Sciences Int'l. (Holdings), we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CK Life Sciences Int'l. (Holdings)'s assets?
Raw Data
DB:LSI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in HKD HK$0.43
SEHK:775 Share Price * SEHK (2020-04-03) in HKD HK$0.93
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:LSI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:775 Share Price ÷ Book Value per Share (both in HKD)

= 0.93 ÷ 0.43

2.14x

* Primary Listing of CK Life Sciences Int'l. (Holdings).

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CK Life Sciences Int'l. (Holdings) is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CK Life Sciences Int'l. (Holdings)'s value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CK Life Sciences Int'l. (Holdings) has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LSI Future Performance

 How is CK Life Sciences Int'l. (Holdings) expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CK Life Sciences Int'l. (Holdings) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CK Life Sciences Int'l. (Holdings) expected to grow at an attractive rate?
  • Unable to compare CK Life Sciences Int'l. (Holdings)'s earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare CK Life Sciences Int'l. (Holdings)'s earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare CK Life Sciences Int'l. (Holdings)'s revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:LSI Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LSI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LSI Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2019-12-31 4,967 379 182
2019-09-30 5,128 337 223
2019-06-30 5,288 295 263
2019-03-31 5,261 263 263
2018-12-31 5,233 231 263
2018-09-30 5,077 261
2018-06-30 4,920 237 259
2018-03-31 4,807 186 259
2017-12-31 4,693 135 258
2017-09-30 4,674 247
2017-06-30 4,655 352 236
2017-03-31 4,762 396 244

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if CK Life Sciences Int'l. (Holdings) is high growth as no earnings estimate data is available.
  • Unable to determine if CK Life Sciences Int'l. (Holdings) is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LSI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from CK Life Sciences Int'l. (Holdings) Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LSI Past Financials Data
Date (Data in HKD Millions) EPS *
2019-12-31 0.02
2019-09-30 0.02
2019-06-30 0.03
2019-03-31 0.03
2018-12-31 0.03
2018-09-30 0.03
2018-06-30 0.03
2018-03-31 0.03
2017-12-31 0.03
2017-09-30 0.03
2017-06-30 0.02
2017-03-31 0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CK Life Sciences Int'l. (Holdings) will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether CK Life Sciences Int'l. (Holdings) is trading at CK Life Sciences Int'l. (Holdings)'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. CK Life Sciences Int'l. (Holdings)'s future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. CK Life Sciences Int'l. (Holdings)'s competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess CK Life Sciences Int'l. (Holdings)'s future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CK Life Sciences Int'l. (Holdings) has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LSI Past Performance

  How has CK Life Sciences Int'l. (Holdings) performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CK Life Sciences Int'l. (Holdings)'s growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CK Life Sciences Int'l. (Holdings)'s year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • CK Life Sciences Int'l. (Holdings)'s 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • CK Life Sciences Int'l. (Holdings)'s 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
CK Life Sciences Int'l. (Holdings)'s revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CK Life Sciences Int'l. (Holdings) Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LSI Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 4,967.02 181.74 552.25
2019-09-30 5,127.66 222.53 546.37
2019-06-30 5,288.30 263.32 540.50
2019-03-31 5,260.64 263.16 532.62
2018-12-31 5,232.99 263.00 524.74
2018-09-30 5,076.69 261.03 516.87
2018-06-30 4,920.39 259.06 509.00
2018-03-31 4,806.76 258.73 508.16
2017-12-31 4,693.13 258.40 507.32
2017-09-30 4,673.98 247.11 512.78
2017-06-30 4,654.83 235.82 518.24
2017-03-31 4,761.69 244.39 519.95
2016-12-31 4,868.54 252.96 521.67
2016-09-30 4,933.13 239.79 516.06
2016-06-30 4,997.71 227.61 510.45
2016-03-31 4,958.51 223.23 501.08
2015-12-31 4,919.31 218.86 491.72
2015-09-30 4,952.91 284.19 494.80
2015-06-30 4,986.51 295.62 497.89
2015-03-31 4,970.28 279.59 497.94
2014-12-31 4,954.04 263.56 497.99
2014-09-30 4,930.29 249.62 494.65
2014-06-30 4,906.54 235.69 491.32
2014-03-31 4,938.74 232.35 490.64
2013-12-31 4,970.93 229.01 489.96
2013-09-30 4,850.54 214.82 479.99
2013-06-30 4,730.15 200.63 470.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • CK Life Sciences Int'l. (Holdings) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • CK Life Sciences Int'l. (Holdings) used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • CK Life Sciences Int'l. (Holdings)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess CK Life Sciences Int'l. (Holdings)'s performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CK Life Sciences Int'l. (Holdings) has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LSI Health

 How is CK Life Sciences Int'l. (Holdings)'s financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CK Life Sciences Int'l. (Holdings)'s finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CK Life Sciences Int'l. (Holdings)'s short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • CK Life Sciences Int'l. (Holdings)'s cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CK Life Sciences Int'l. (Holdings)'s finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CK Life Sciences Int'l. (Holdings) Company Filings, last reported 3 months ago.

DB:LSI Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4,174.75 5,106.43 713.14
2019-09-30 4,174.75 5,106.43 713.14
2019-06-30 4,322.83 4,807.60 688.64
2019-03-31 4,322.83 4,807.60 688.64
2018-12-31 4,419.84 4,816.25 784.96
2018-09-30 4,419.84 4,816.25 784.96
2018-06-30 4,603.12 4,845.09 1,065.51
2018-03-31 4,603.12 4,845.09 1,065.51
2017-12-31 4,756.71 4,595.21 1,054.13
2017-09-30 4,756.71 4,595.21 1,054.13
2017-06-30 4,617.36 4,255.35 832.12
2017-03-31 4,617.36 4,255.35 832.12
2016-12-31 4,403.04 4,027.25 878.99
2016-09-30 4,452.38 4,027.25 878.99
2016-06-30 4,478.26 4,211.42 791.29
2016-03-31 4,478.26 4,211.42 791.29
2015-12-31 4,259.26 4,193.57 869.13
2015-09-30 4,338.58 4,193.57 869.13
2015-06-30 4,659.47 4,205.24 748.11
2015-03-31 4,659.47 4,205.24 748.11
2014-12-31 4,874.97 4,360.97 1,038.95
2014-09-30 4,874.97 4,360.97 1,038.95
2014-06-30 5,515.97 3,989.17 702.41
2014-03-31 5,515.97 3,989.17 702.41
2013-12-31 5,200.30 3,791.75 817.77
2013-09-30 5,200.30 3,791.75 817.77
2013-06-30 5,205.96 3,583.07 613.45
  • CK Life Sciences Int'l. (Holdings)'s level of debt (122.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (89.5% vs 122.3% today).
  • Debt is not well covered by operating cash flow (7.4%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess CK Life Sciences Int'l. (Holdings)'s financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CK Life Sciences Int'l. (Holdings) has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LSI Dividends

 What is CK Life Sciences Int'l. (Holdings)'s current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.08%
Current annual income from CK Life Sciences Int'l. (Holdings) dividends.
If you bought €2,000 of CK Life Sciences Int'l. (Holdings) shares you are expected to receive €22 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • CK Life Sciences Int'l. (Holdings)'s pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.7%).
  • CK Life Sciences Int'l. (Holdings)'s dividend is below the markets top 25% of dividend payers in Germany (4.86%).
Upcoming dividend payment

Purchase CK Life Sciences Int'l. (Holdings) before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LSI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LSI Past Annualized Dividends Data
Date (Data in HK$) Dividend per share (annual) Avg. Yield (%)
2020-03-17 0.010 1.230
2019-03-19 0.010 2.025
2018-04-03 0.010 2.140
2018-03-13 0.010 1.725
2017-03-31 0.010 1.607
2017-03-21 0.010 1.470
2016-04-07 0.009 1.280
2016-03-14 0.009 1.404
2015-03-30 0.008 1.093
2015-02-24 0.008 1.052
2014-04-04 0.007 0.884
2014-02-24 0.007 0.858
2013-04-02 0.006 0.873
2013-03-07 0.006 0.870
2012-03-07 0.005 0.941
2011-02-28 0.005 1.190

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, CK Life Sciences Int'l. (Holdings) has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but CK Life Sciences Int'l. (Holdings) only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of CK Life Sciences Int'l. (Holdings)'s earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.9x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CK Life Sciences Int'l. (Holdings)'s dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CK Life Sciences Int'l. (Holdings) afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CK Life Sciences Int'l. (Holdings) has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LSI Management

 What is the CEO of CK Life Sciences Int'l. (Holdings)'s salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hing Lam Kam
COMPENSATION HK$3,825,000
AGE 73
CEO Bio

Mr. Kam Hing Lam, B.ScE, MBA has been Deputy Managing Director and Executive Director of CK Asset Holdings Limited (formerly Cheung Kong Property Holdings Limited) since February 26, 2015. Mr. Kam has been Deputy Managing Director of Cheung Kong since 1993. He joined the CK Group in 1993. Mr. Kam has been Group Managing Director of CK Infrastructure Holdings Limited (alternate name: Cheung Kong Infrastructure Holdings Ltd.) since May 29, 1996. Mr. Kam has been Deputy Managing Director at CK Hutchison Holdings Limited since January 9, 2015 and is its Executive Director since February 15, 1993. Mr. Kam serves as Non-Executive Board Member of ETSA Utilities Finance Pty Ltd. He serves as the Chief Executive Officer and President of CK Life Sciences Int'l., Inc. and CK Life Sciences Int'l., (Holdings) Inc. and is responsible for Overall Strategic Direction and Key Operating Decisions. He has been an Executive Director of CK Life Sciences Int'l., (Holdings) Inc. and Hutchison Whampoa Limited since August 31, 1993. He served as Group Managing Director of SA Power Networks. He served as Executive Director of Power Assets Holdings Limited (formerly, Hongkong Electric Holdings Ltd) from May 13, 1993 to January 29, 2013. Mr. Kam joined CK Life Sciences Int'l., (Holdings) Inc. in December 1999 and has played a leading role in developing its corporate direction and strategic vision and in guiding in pursuit of its corporate business and operational objectives. He has been the Chairman of Hui Xian Asset Management Limited as the manager of Hui Xian REIT since December 2010. He is Founding Chairman of Beijing Oriental Plaza Co., Ltd. Mr. Kam has been a Non Executive Director of Northumbrian Water Group Limited since October 14, 2011. He has been a Non-Executive Director of Northumbrian Water Limited since October 2011. He has been a Director of South Eastern Power Networks Plc since November 24, 2010 and CKI UK Co. 6 Ltd. since July 31, 2016. He has been a Director at Electricity First Ltd. since April 23, 2010. He serves as a Director at UK Power Networks Services Holdings Limited, Powercor Australia Ltd., Powercor Network Services Pty Ltd., CitiPower Pty Ltd., and Northern Gas Networks Holdings Ltd. Mr. Kam has been a Director of Northern Gas Networks Limited since May 31, 2005. He serves as an Executive Director at Cheung Kong Infrastructure Holdings Ltd. and PG (April) Limited. He has been a Non-Executive Director of Spark Infrastructure Holdings No. 2 Limited since November 1, 2005. He has been a Director of SA Power Networks since March 8, 2000. He serves as Non-Executive Director of Victoria Power Networks (Finance) Pty Limited. He serves as a Director of Victoria Power Networks Pty Limited (formerly CHEDHA Holdings Pty Limited). He has been a Director of Australian Gas Networks Limited (formerly Envestra Limited) since September 2014 and served as its Non Executive Director from September 1999 to August 27, 2007. He served as a Director of Spark Infrastructure RE Limited at Spark Infrastructure Trust until May 28, 2010. He served as a Director of The Hongkong Electric Company Limited. He served as a Director of HK Electric Investments and HK Electric Investments Limited. Mr. Kam served as a Non-Executive Director of Cambridge Water Plc from April 28, 2004 to August 02, 2011. Mr. Kam is a director of certain substantial shareholders of Cheung Kong Infrastructure Holdings. He is a director of certain companies controlled by certain substantial shareholders of Cheung Kong Infrastructure Holdings. He served as a Non Executive Director of Spark Infrastructure Group from November 01, 2005 to May 28, 2010. He served as a Non Executive Director at Envestra Limited from September 1999 to August 27, 2007. He is Manager of Hui Xian REIT. Mr. Kam holds a Bachelor of Science degree in Engineering from the University of Hong Kong in November 1969 and a Master’s degree in Business Administration from the Chinese University of Hong Kong in December 1980.

CEO Compensation
  • Hing Lam's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Hing Lam's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CK Life Sciences Int'l. (Holdings) management team in years:

1.4
Average Tenure
61
Average Age
  • The average tenure for the CK Life Sciences Int'l. (Holdings) management team is less than 2 years, this suggests a new team.
Management Team

Victor Li

TITLE
Executive Chairman
COMPENSATION
HK$75K
AGE
55

Hing Lam Kam

TITLE
President
COMPENSATION
HK$4M
AGE
73

Alan Abel Yu

TITLE
VP, COO
COMPENSATION
HK$13M
AGE
63

Edmond Ip

TITLE
Senior VP
COMPENSATION
HK$2M
AGE
67

Melvin Toh

TITLE
Chief Scientific Officer & Executive Director
COMPENSATION
HK$4M
AGE
52
TENURE
1.4 yrs

Kee Chu

TITLE
Vice President
COMPENSATION
HK$3M
AGE
74
TENURE
1.4 yrs

Jerry Mo

TITLE
Vice President of Finance
AGE
59

Jane Lee

TITLE
Chief Manager of Personnel & Administration
AGE
59

Dennis Hon

TITLE
Legal Counsel
AGE
65
TENURE
17.8 yrs

Wendy Tong Barnes

TITLE
Chief Corporate Affairs Officer
AGE
58
Board of Directors Tenure

Average tenure and age of the CK Life Sciences Int'l. (Holdings) board of directors in years:

17.8
Average Tenure
65
Average Age
  • The average tenure for the CK Life Sciences Int'l. (Holdings) board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Victor Li

TITLE
Executive Chairman
COMPENSATION
HK$75K
AGE
55
TENURE
18 yrs

Hing Lam Kam

TITLE
President
COMPENSATION
HK$4M
AGE
73

Alan Abel Yu

TITLE
VP, COO
COMPENSATION
HK$13M
AGE
63

Edmond Ip

TITLE
Senior VP
COMPENSATION
HK$2M
AGE
67

Melvin Toh

TITLE
Chief Scientific Officer & Executive Director
COMPENSATION
HK$4M
AGE
52
TENURE
1.4 yrs

Leon Lam

TITLE
Chairman of Australian Agribusiness Pty Ltd
COMPENSATION
HK$3M
AGE
61

Keith Frankel

TITLE
Co-Chairman of Vitaquest International LLC
AGE
54

Eva Kwok

TITLE
Independent Non-Executive Director
COMPENSATION
HK$180K
AGE
76
TENURE
17.8 yrs

Kai Cheong Kwan

TITLE
Independent Non-executive Director
COMPENSATION
HK$155K
AGE
69
TENURE
1.9 yrs

Peter Peace Tulloch

TITLE
Non-Executive Director
COMPENSATION
HK$75K
AGE
75
TENURE
18 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CK Life Sciences Int'l. (Holdings)'s management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CK Life Sciences Int'l. (Holdings) has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LSI News

Simply Wall St News

LSI Company Info

Description

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research, development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines, vitamins, nutritional supplements, and cosmetics; licensing registration activities and the importation of finished agricultural goods; holding land and building; financing and trustee activities; investment in financial instruments, as well as vineyards and wineries; trading of biotechnology products and nutritional supplements; and the manufacturing, wholesale, retailing, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; produces, refines, and distributes salt products; and provides services in the research and development of bio-technology and life sciences technology products. Further, it engages in the discovery, development, manufacture, and commercialization of drug products to treat pain and melanoma; and supply of raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food segments. Additionally, the company offers packing and asset management services. CK Life Sciences Int'l., (Holdings) Inc. is headquartered in Tai Po, Hong Kong.

Details
Name: CK Life Sciences Int'l., (Holdings) Inc.
LSI
Exchange: DB
Founded:
HK$1,068,623,313
9,611,073,000
Website: http://www.ck-lifesciences.com
Address: CK Life Sciences Int'l., (Holdings) Inc.
2 Dai Fu Street,
Tai Po Industrial Estate,
Tai Po,
New Territories, Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 775 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 16. Jul 2002
OTCPK CKLS.F Ordinary Shares Pink Sheets LLC US USD 16. Jul 2002
DB LSI Ordinary Shares Deutsche Boerse AG DE EUR 16. Jul 2002
BRSE LSI Ordinary Shares Berne Stock Exchange CH CHF 16. Jul 2002
Number of employees
Current staff
Staff numbers
1,829
CK Life Sciences Int'l. (Holdings) employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:01
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/04/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.